Lorzone
Loading...Lorzone Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Serious (including fatal) hepatocellular toxicity has been reported rarely in patients receiving chlorzoxazone. The mechanism is unknown but appears to be idiosyncratic and unpredictable. Factors predisposing patients to this rare event are not known. Patients should be instructed to report early signs and/ or symptoms of hepatoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, or jaundice. Lorzone® should be discontinued immediately and a physician consulted if any of these signs or symptoms develop. Lorzone® use should also be discontinued if a patient develops abnormal liver enzymes (e.g., AST, ALT, alkaline phosphates and bilirubin).
The concomitant use of alcohol or other central nervous system depressants may have an additive effect.
Usage in Pregnancy: The safe use of Lorzone® has not been established with respect to the possible adverse effects upon fetal development. Therefore, it should be used in women of childbearing potential only when, in the judgment of the physician, the potential benefits outweigh the possible risks.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Lorzone® is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Chlorzoxazone does not directly relax tense skeletal muscles in man.
History
There is currently no drug history available for this drug.
Other Information
Each 375 mg Lorzone® tablet contains: chlorzoxazone USP 375 mg.
Each 750 mg Lorzone® tablet contains: chlorzoxazone USP 750 mg.
Chemical Name: 5-Chloro-2-benzoxazolinone.
Structural Formula:
Molecular Formula: C7H4CINO2
Molecular Weight: 169.56
Chlorzoxazone USP is a white or practically white, practically odorless, crystalline powder. Chlorzoxazone is slightly soluble in water; sparingly soluble in alcohol, in isopropyl alcohol, and in methanol; soluble in solutions of alkali hydroxides and ammonia.
Inactive ingredients: anhydrous lactose, croscarmellose sodium, docusate sodium, magnesium stearate, microcrystalline cellulose, pregelatinized corn starch and sodium benzoate.
Sources
Lorzone Manufacturers
-
Vertical Pharmaceuticals, Inc.
![Lorzone (Chlorzoxazone) Tablet [Vertical Pharmaceuticals, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Lorzone | Vertical Pharmaceuticals, Llc
Usual Adult Dosage
Lorzone® Tablets (chlorzoxazone USP) 375 mg:
One tablet three or four times daily. If adequate response is not obtained with this dose, the 375 mg tablets may be increased to two tablets (750 mg) three or four times daily. As improvement occurs dosage can usually be reduced.
Lorzone® Tablets (chlorzoxazone USP) 750 mg:
1/3 tablet (250 mg) three or four times daily. Initial dosage for painful musculoskeletal conditions should be 2/3 tablet (500 mg) three or four times daily. If adequate response is not obtained with this dose, it may be increased to one tablet (750 mg) three or four times daily. As improvement occurs dosage can usually be reduced.
Login To Your Free Account